

Consultation on draft quality standard – deadline for comments 5pm on 12/03/19 email: QSconsultations@nice.org.uk

	<p>Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.</p> <p>We would like to hear your views on these questions:</p> <ol style="list-style-type: none"> 1. Does this draft quality standard accurately reflect the key areas for quality improvement? 2. If the systems and structures were available, do you think it would be possible to collect the data for the proposed quality measures? 3. Do you think each of the statements in this draft quality standard would be achievable by local services given the net resources needed to deliver them? Please describe any resource requirements that you think would be necessary for any statement. Please describe any potential cost savings or opportunities for disinvestment. 4. Do you have an example from practice of implementing the NICE guideline(s) that underpins this quality standard? If so, please submit your example to the NICE local practice collection on the NICE website. Examples of using NICE quality standards can also be submitted. 5. For draft statement 4: Should this statement be aimed at local authorities? If not, who should be organising health promotion activities to raise public awareness about how to prevent Lyme disease?
<p>Organisation name – stakeholder or respondent (if you are responding as an individual rather than a registered stakeholder please leave blank):</p>	<p>British Association of Dermatologists</p>
<p>Disclosure Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry.</p>	<p>[No]</p>

Consultation on draft quality standard – deadline for comments 5pm on 12/03/19 email: QSconsultations@nice.org.uk

Name of commentator person completing form:		[Prof Nick Levell on behalf of the British Association of Dermatologists' Therapy & Guidelines sub-committee]	
Supporting the quality standard - Would your organisation like to express an interest in formally supporting this quality standard? More information.		[Answer Yes or No]	
Type		[office use only]	
Comment number	Section	Statement number	Comments
			Insert each comment in a new row. Do not paste other tables into this table because your comments could get lost – type directly into this table.
1			The clinical diagnosis of erythema migrans can be difficult. Experienced GPs are often uncertain about the diagnosis and require support from secondary care. It can sometimes be difficult to distinguish from urticaria, urticarial vasculitis and partially treatment tinea corporis. Erythema annulare centrifugum looks similar sometimes. Erythema multiforme and fixed drug eruptions have also been misdiagnosed as Lyme disease. The guideline and quality standard should say something about getting dermatology advice if there is diagnostic uncertainty.
2			The MRCGP eLearning package that is linked to the document goes to a page that requires a login. The educational package should be accessible.
3			Acrodermatitis Chronica Atrophicans is very rare in the UK. There have been few cases reported since 1994.

Insert extra rows as needed

Checklist for submitting comments

- Use this comment form and submit it as a Word document (not a PDF).
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include section number of the text each comment is about eg. introduction; quality statement 1; quality statement 2 (measure).
- If commenting on a specific quality statement, please indicate the particular sub-section (for example, statement, measure or audience descriptor).

Please return to: QSconsultations@nice.org.uk

Consultation on draft quality standard – deadline for comments 5pm on 12/03/19 email: QSconsultations@nice.org.uk

- Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
- Do not paste other tables into this table – type directly into the table.
- Underline and highlight any confidential information or other material that you do not wish to be made public.
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, comment forms do not include attachments such as research articles, letters or leaflets (for copyright reasons). We return comment forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.

You can see any guidance and quality standards that we have produced on topics related to this quality standard by checking [NICE Pathways](#).

Note: We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received from registered stakeholders and respondents during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.